Secure Drug Supply Chain Act of 2026
The source supplies the latest action, but no lifecycle stage.
Latest action (21 Jul 2026): Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
What this bill does
S. 5043, the Secure Drug Supply Chain Act of 2026, aims to prevent the importation of counterfeit, unapproved, misbranded, or adulterated drugs into the United States, particularly from China and other countries designated as adversarial. The bill directs the Food and Drug Administration (FDA) to enhance safeguards for imported drug products, increase visibility into the U.S. pharmaceutical supply chain, and reduce reliance on certain foreign sources for active pharmaceutical ingredients and key starting materials.
This legislation would affect drug manufacturers and importers by requiring more frequent reporting on the origin of ingredients and potentially prohibiting the import of drugs from establishments found to use forced labor or violate U.S. sanctions. It also outlines procedures for refusing entry, destroying, and reporting on certain imported drugs. The bill also requires the FDA to analyze U.S. vulnerabilities related to dependence on foreign pharmaceutical supply chains and to issue new regulations.
S. 5043 was introduced in the Senate on July 21, 2026, by Senator Ted Budd. It has been read twice and referred to the Committee on Health, Education, Labor, and Pensions. The bill's next steps would involve committee review, potential amendments, and votes in the Senate before it could proceed to the House of Representatives.
Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.
Timeline
21 Jul 2026
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Common questions
- What does S. 5043 do?
- S. 5043, the Secure Drug Supply Chain Act of 2026, aims to prevent the importation of counterfeit, unapproved, misbranded, or adulterated drugs into the United States, particularly from China and other countries designated as adversarial. The bill directs the Food and Drug Administration (FDA) to enhance safeguards for imported drug products, increase visibility into the U.S. pharmaceutical supply chain, and reduce reliance on certain foreign sources for active pharmaceutical ingredients and key starting materials. This legislation would affect drug manufacturers and importers by requiring more frequent reporting on the origin of ingredients and potentially prohibiting the import of drugs from establishments found to use forced labor or violate U.S. sanctions. It also outlines procedures for refusing entry, destroying, and reporting on certain imported drugs. The bill also requires the FDA to analyze U.S. vulnerabilities related to dependence on foreign pharmaceutical supply chains and to issue new regulations. S. 5043 was introduced in the Senate on July 21, 2026, by Senator Ted Budd. It has been read twice and referred to the Committee on Health, Education, Labor, and Pensions. The bill's next steps would involve committee review, potential amendments, and votes in the Senate before it could proceed to the House of Representatives.
- Has S. 5043 become law?
- The source does not supply a confirmed lifecycle stage for S. 5043. Check the latest action and official source below.
- Who sponsored S. 5043?
- S. 5043 was sponsored by Sen. Budd, Ted [R-NC] (R-NC), with 2 cosponsors.
- What's the latest action on S. 5043?
- Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (21 Jul 2026).
Related bills in Health
Choices for Increased Mobility Act of 2026
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
340B Rebate Model Delay Act
Lower Premiums, Faster Payments Act
More bills from Sen. Budd, Ted [R-NC]
Fort Bragg Land Transfer for Veterans Act
SCALE Biology Act
Combatting the Persecution of Religious Groups in the People’s Republic of China Act
FIRST Act
Bill100 mirrors the public U.S. legislative record from Congress.gov and GovTrack and adds plain-English AI summaries. It is an information tool, not legal, compliance or lobbying advice, and it is not affiliated with the U.S. Congress or any government agency. AI summaries can simplify or omit detail — every bill links to the official source; verify there before you rely on it.